Formulating ezetimibe in oral solid preparation has challenged oral hyperlipidemia therapy with ezetimibe. The present work was about formulating a solid self-microemulsifying formulation of ezetimibe and evaluating its in-vitro preparation. The solubility of ezetimibe was determined in various vehicles. Ezetimibe was dispersed with a surfactant used for the self-microemulsifying drug delivery system (SMEDDS), Tween 20, cremophor, peceol and mixture was solidified with maltodextrin. Solid-SMEDDS is prepared using maltodextrin as solid carrier and characterized for drug content, spray dried process yield and flow property which was 91.4%, 56% respectively with good flow property. Saturation solubility of solid SMEDDS shows 93 folds increased solubility. Dissolution studied in 0.1 N HCl and phosphate buffer 7.4 provide higher drug release 82.32% within 15 min compared with marketed formulation. Solid state characterization of solid-SMEDDS shows that the drug is in amorphous form. For improved patient compliance and onset of action oral dispersible tablet was prepared and evaluated. The present research shows that S-SMEDDS is an ideal and promising approach to enhance the solubility and its oral dispersible tablet increase patient compliance. The optimized formulation was then subjected to stability and was found to be stable over three months. It has been found that dissolution profile of ezetimibe from SMEDDS was much improved than ezetimibe.
Loading....